Stambuk D, Vallerich M, Youle M, Rios A, Naylor P, Sarin P, Goldstein A, Gazzard B; International Conference on AIDS.
Int Conf AIDS. 1990 Jun 20-23; 6: 327 (abstract no. 1054).
St. Stephen's/Westminster Hospital, London, England
OBJECTIVE: To evaluate toxicity and safety of administration to humans of HGP-30 vaccine and their antibody response. METHODS: Nineteen Western Blot HIV negative male volunteers were injected intramuscularly with escalating doses (10, 25, 50ug/kg body weight) of a synthetic peptide HGP-30 coupled to Keyhole Limpet Hemocyanin and administered with alum. A total of 3 injections were given at weeks 0, 6, 14 to subjects divided in 3 dose-related groups and monitored two-weekly for evidence of toxicity for a median period of 18 weeks (2-24). RESULTS: Two of 19 volunteers withdrew. In the 17, still in study, there was no evidence of toxicity and the only complaint was a varying degree of pain at the injection site lasting for 1 - 3 days. Six of 15 (40%) humans who received a full vaccination course developed reactivity to p17 and/or p24 on Western Blot. The Western Blot of all other HIV antigens remained negative in all patients except one who had transient weak positivity to p66 and gp120/160. CONCLUSION: HGP-30 vaccine applied in human males seems to be safe, non-toxic and is immunogenic.
Publication Types:
Keywords:
- Animals
- Clinical Trials, Phase I as Topic
- HIV Antigens
- HIV Envelope Protein gp120
- HIV Infections
- Hemocyanin
- Humans
- Male
- Peptides
- Vaccination
- immunology
- keyhole-limpet hemocyanin
Other ID:
UI: 102196903
From Meeting Abstracts